Pub Date : 2020-03-25DOI: 10.3760/CMA.J.CN115356-20200105-00011
Hang Zhou, Yuhan Ma
EB virus (EBV) is a potential oncogenic virus. About 95% of healthy people are infected with EBV and carry it for all life. EBV can induce host cells clonization and transformation. About 2% of tumors are related to EBV infection. In recent years, EBV-induced lymphocyte clonal transformation and the diagnosis and treatment of EBV-related lymphoproliferative diseases have got some progress. Key words: Herpesvirus 4, human; Lymphoma; Transformation; Immunotherapy; Cellular therapy
{"title":"Diagnosis and treatment progress of EB virus-related lymphoproliferative diseases","authors":"Hang Zhou, Yuhan Ma","doi":"10.3760/CMA.J.CN115356-20200105-00011","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115356-20200105-00011","url":null,"abstract":"EB virus (EBV) is a potential oncogenic virus. About 95% of healthy people are infected with EBV and carry it for all life. EBV can induce host cells clonization and transformation. About 2% of tumors are related to EBV infection. In recent years, EBV-induced lymphocyte clonal transformation and the diagnosis and treatment of EBV-related lymphoproliferative diseases have got some progress. \u0000 \u0000 \u0000Key words: \u0000Herpesvirus 4, human; Lymphoma; Transformation; Immunotherapy; Cellular therapy","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"29 1","pages":"141-145"},"PeriodicalIF":0.0,"publicationDate":"2020-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42591420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-03-25DOI: 10.3760/CMA.J.CN115356-20191006-00193
Lina Hu, M. Xie, Guoqiang Li, Chun Feng, P. Ke, Xinyou Zhang, Jihao Zhou
Objective To investigate the clinical efficacy of P-GEMOX (pegaspargase, gemcitabine and oxaliplatin) as a first-line regimen for the treatment of primary extranasal nasal-type NK/T cell lymphoma (NKTCL). Methods The clinical manifestations, treatment response and prognosis of 7 patients with primary extranasal nasal-type NKTCL who underwent P-GEMOX chemotherapy as a first-line therapy in Shenzhen People's Hospital from September 2015 to October 2018 were retrospectively analyzed. Results The median age of 7 patients with primary extranasal nasal-type NKTCL was 41 years old (27-74 years old), which was more commonly found in males (6 cases); the primary and invading extranasal sites included ileocecal, lymph nodes, skin, testis, adrenal gland, central nervous system, etc. The P-GEMOX regimen was used as a first-line therapy, although some patients had a short-term effect, all patients eventually progressed rapidly and died. The overall survival time was 2 weeks to 21 months. Conclusion The short-term efficacy of P-GEMOX as a first-line therapy for the treatment of primary extranasal nasal-type NKTCL is acceptable, but the long-term efficacy is poor. Key words: Lymphoma, NK/T cell; Extranasal; Antineoplastic combined chemotherapy protocols; P-GEMOX regimen
{"title":"Clinical observation of primary extranasal nasal-type NK/T cell lymphoma treated with P-GEMOX as a first-line regimen","authors":"Lina Hu, M. Xie, Guoqiang Li, Chun Feng, P. Ke, Xinyou Zhang, Jihao Zhou","doi":"10.3760/CMA.J.CN115356-20191006-00193","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115356-20191006-00193","url":null,"abstract":"Objective \u0000To investigate the clinical efficacy of P-GEMOX (pegaspargase, gemcitabine and oxaliplatin) as a first-line regimen for the treatment of primary extranasal nasal-type NK/T cell lymphoma (NKTCL). \u0000 \u0000 \u0000Methods \u0000The clinical manifestations, treatment response and prognosis of 7 patients with primary extranasal nasal-type NKTCL who underwent P-GEMOX chemotherapy as a first-line therapy in Shenzhen People's Hospital from September 2015 to October 2018 were retrospectively analyzed. \u0000 \u0000 \u0000Results \u0000The median age of 7 patients with primary extranasal nasal-type NKTCL was 41 years old (27-74 years old), which was more commonly found in males (6 cases); the primary and invading extranasal sites included ileocecal, lymph nodes, skin, testis, adrenal gland, central nervous system, etc. The P-GEMOX regimen was used as a first-line therapy, although some patients had a short-term effect, all patients eventually progressed rapidly and died. The overall survival time was 2 weeks to 21 months. \u0000 \u0000 \u0000Conclusion \u0000The short-term efficacy of P-GEMOX as a first-line therapy for the treatment of primary extranasal nasal-type NKTCL is acceptable, but the long-term efficacy is poor. \u0000 \u0000 \u0000Key words: \u0000Lymphoma, NK/T cell; Extranasal; Antineoplastic combined chemotherapy protocols; P-GEMOX regimen","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"29 1","pages":"160-164"},"PeriodicalIF":0.0,"publicationDate":"2020-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44531896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective To improve the understanding of splenic marginal zone lymphoma (SMZL) with villous lymphocytes. Method: A retrospective analysis was conducted on the data of a patient with SMZL and villous lymphocytes admitted to the First People's Hospital of Xiangyang City, Affiliated to Hubei Medical College, and relevant literature at home and abroad was reviewed. The patient had a splenomegaly, increased white blood cells, and some lymphocytes with spicule like changes were observed in peripheral blood and bone marrow; Immunophenotyping showed abnormal B lymphocytes accounting for 81.07%, positive for CD11c, CD20, FMC7, CD22, cKappa, and CD79b, partially positive for sIgD, and weakly positive for CD19, CD81, and sIgM; The proportion of lymphocytes in bone marrow disease is increased, with mature morphology. Reticular fiber staining is MF-1 grade, and Annexin is negative. Focal infiltration of CD20+cells in the sinuses is visible, and MYD88 gene testing is negative. Chromosome analysis shows no analyzable mitosis, meeting the diagnostic criteria for SMZL with villous lymphocytes. Treatment with rituximab resulted in a decrease in white blood cell count to normal and improved condition before discharge. Follow up for 2 months generally shows good condition. Conclusion: SMZL with villous lymphocytes is rare, and the diagnosis should be based on a comprehensive analysis of the patient's medical history, clinical manifestations, cell morphology, histopathology, immune typing, and gene testing. The diagnosis can be made through spleen pathology, and rituximab is the preferred treatment.
{"title":"Splenic marginal zone lymphoma with villous lymphocytes: report of one case and review of literature","authors":"Li He, Y. Bao, Hai-yan Wang, Yan Liang, Wei Wei","doi":"10.3760/CMA.J.CN115356-2018-1031-00301","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115356-2018-1031-00301","url":null,"abstract":"目的 \u0000提高对脾边缘区淋巴瘤（SMZL）伴绒毛状淋巴细胞的认识。 \u0000 \u0000 \u0000方法 \u0000回顾分析湖北医药学院附属襄阳市第一人民医院收治的1例SMZL伴绒毛状淋巴细胞患者资料，并复习国内外相关文献。 \u0000 \u0000 \u0000结果 \u0000该患者巨脾，白细胞增多，外周血及骨髓见部分淋巴细胞毛刺样改变；免疫分型示异常B淋巴细胞占81.07%，CD11c、CD20、FMC7、CD22、cKappa、CD79b阳性，sIgD部分阳性，CD19、CD81、sIgM弱阳性；骨髓病淋巴细胞比例增高，形态成熟，网状纤维染色MF-1级，Annexin阴性，局灶可见CD20+细胞窦内浸润，MYD88基因检测阴性，染色体分析未见可分析分裂象，符合SMZL伴绒毛状淋巴细胞的诊断标准。给予利妥昔单抗治疗，白细胞计数降至正常，病情好转出院。随访2个月一般情况良好。 \u0000 \u0000 \u0000结论 \u0000SMZL伴绒毛状淋巴细胞较罕见，诊断应结合患者病史、临床表现、细胞形态、组织病理、免疫分型、基因检测综合分析，通过脾脏病理可确诊，治疗首选利妥昔单抗。","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"29 1","pages":"189-192"},"PeriodicalIF":0.0,"publicationDate":"2020-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42871521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-03-25DOI: 10.3760/CMA.J.CN115356-20191220-00265
Q. Lin, Yan Yan
Chimeric antigen receptor T-cell (CAR-T) therapy has made a breakthrough in the treatment of hematological tumors. CAR-T therapy targeting kappa immunoglobulin light chain, CD19 and B-cell mature antigen (BCMA) have been used to treat relapsed/refractory MM (RRMM) patients, and the effect of anti-BCMA CAR-T is the best. However, the negative or positive recurrence of BCMA leads to a short progression-free survival (PFS), the improvement of the chimeric antigen receptor (CAR) structure targeted BCMA, dual-targeted CAR-T and CAR-T combined with small molecular drugs as well as other measures have become the focuses of CAR-T in the treatment of RRMM. Key words: Multiple myeloma; Chimeric antigen receptor T-cell; B-cell maturation antigen; CD19
{"title":"Progress of chimeric antigen receptor T-cell therapy for multiple myeloma","authors":"Q. Lin, Yan Yan","doi":"10.3760/CMA.J.CN115356-20191220-00265","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115356-20191220-00265","url":null,"abstract":"Chimeric antigen receptor T-cell (CAR-T) therapy has made a breakthrough in the treatment of hematological tumors. CAR-T therapy targeting kappa immunoglobulin light chain, CD19 and B-cell mature antigen (BCMA) have been used to treat relapsed/refractory MM (RRMM) patients, and the effect of anti-BCMA CAR-T is the best. However, the negative or positive recurrence of BCMA leads to a short progression-free survival (PFS), the improvement of the chimeric antigen receptor (CAR) structure targeted BCMA, dual-targeted CAR-T and CAR-T combined with small molecular drugs as well as other measures have become the focuses of CAR-T in the treatment of RRMM. \u0000 \u0000 \u0000Key words: \u0000Multiple myeloma; Chimeric antigen receptor T-cell; B-cell maturation antigen; CD19","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"29 1","pages":"136-140"},"PeriodicalIF":0.0,"publicationDate":"2020-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47379192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-03-25DOI: 10.3760/CMA.J.CN115356-20200201-00028
Zeyu Lin
The clinical study of multiple myeloma at various stages has been reported at 2019 American Society of Hematology Annual Meeting. This article focuses on several key studies of the treatment of high-risk smoking multiple myeloma (HR-SMM), newly diagnosed multiple myeloma (NDMM) and relapsed/refractory multiple myeloma (RRMM), especially the chimeric antigen receptor T-cell (CAR-T) therapy, in order to guide clinical selection of better treatment options. However, most of these studies are phase Ⅰ-Ⅱ studies, and the median follow-up period is short, the long-term follow-up and the results of phase Ⅲ studies with enlarged samples are needed to further determine the effectiveness and safety of each treatment plan. Key words: Multiple myeloma; Treatment; Immunotherapy
{"title":"Treatment progress of multiple myeloma","authors":"Zeyu Lin","doi":"10.3760/CMA.J.CN115356-20200201-00028","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115356-20200201-00028","url":null,"abstract":"The clinical study of multiple myeloma at various stages has been reported at 2019 American Society of Hematology Annual Meeting. This article focuses on several key studies of the treatment of high-risk smoking multiple myeloma (HR-SMM), newly diagnosed multiple myeloma (NDMM) and relapsed/refractory multiple myeloma (RRMM), especially the chimeric antigen receptor T-cell (CAR-T) therapy, in order to guide clinical selection of better treatment options. However, most of these studies are phase Ⅰ-Ⅱ studies, and the median follow-up period is short, the long-term follow-up and the results of phase Ⅲ studies with enlarged samples are needed to further determine the effectiveness and safety of each treatment plan. \u0000 \u0000 \u0000Key words: \u0000Multiple myeloma; Treatment; Immunotherapy","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"29 1","pages":"132-135"},"PeriodicalIF":0.0,"publicationDate":"2020-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42678937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: To improve the understanding of chronic lymphocytic leukemia (CLL) with secondary tumors. Method: Two CLL patients treated with ibutinib at the Affiliated Hospital of Qingdao University were reported, who were complicated with abdominal gastrointestinal adenocarcinoma and squamous cell carcinoma, respectively. Relevant literature was reviewed. As a result, two CLL patients were diagnosed with a second tumor during the administration of ibutinib. Conclusion: The condition of CLL should be actively evaluated, strict adherence to CLL treatment indication standards, and early detection and treatment of secondary tumors.
{"title":"Ibrutinib in treatment of chronic lymphocytic leukemia with a second tumor: report of two cases and review of literature","authors":"Qian Yang, Jun-xia Huang, S. Nie, Tianlan Li, Yan Gao, Xueshen Yan, Shanshan Liu, Chunxia Mao, Jingjing Zhou, Yujie Xu, Fanjun Meng, Xianqi Feng","doi":"10.3760/CMA.J.CN115356-20190828-00168","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115356-20190828-00168","url":null,"abstract":"目的 \u0000提高对慢性淋巴细胞白血病（CLL）合并第二肿瘤的认识。 \u0000 \u0000 \u0000方法 \u0000报道青岛大学附属医院2例给予伊布替尼治疗的CLL患者，分别合并腹腔消化道来源腺癌和鳞状细胞癌，并复习相关文献。 \u0000 \u0000 \u0000结果 \u00002例CLL患者在确诊后，在给予伊布替尼过程中合并第二肿瘤。 \u0000 \u0000 \u0000结论 \u0000应积极评估CLL病情，严格遵守CLL治疗指征标准，早期发现治疗第二肿瘤。","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"29 1","pages":"185-187"},"PeriodicalIF":0.0,"publicationDate":"2020-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43368400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-03-25DOI: 10.3760/CMA.J.CN115356-20190617-00117
Jin Zhao, L. Su, T. Guan, Jiangtao Wang, Xiaolan Liu, Li Ma
Objective To investigate the effect of infused CD34+ cell count on hematopoietic recovery and prognosis of non-Hodgkin lymphoma (NHL) patients after autologous peripheral blood hematopoietic stem cell transplantation (APBSCT). Methods The data of 60 NHL patients who underwent APBSCT from May 2010 to May 2016 in the Affiliated Cancer Hospital of Shanxi Medical University was retrospectively analyzed, including 32 B-NHL patients and 28 T-NHL patients. The patients were grouped according to the receiver operating characteristic curve (ROC) threshold, and the hematopoietic reconstruction after transplantation was analyzed. The relationship between the infused CD34+ cell count and prognosis was analyzed. The prognostic factors were analyzed using univariate and multivariate analyses. Results The CD34+ cell count threshold was determined to be 4.35×106/kg based on ROC. In CD34+ cell count≥ 4.35×106/kg group (20 cases) and CD34+ cell count 60 years old, Ann Arbor stage Ⅲ-Ⅳ, international prognostic index (IPI) score > 2 and infused CD34+ cell count < 4.35×106/kg (all P < 0.05). Multivariate analysis showed that IPI score and infused CD34+ cell count were both independent predictive factors of PFS (RR = 0.333, 95% CI 0.112-0.994, P = 0.049; RR = 0.190, 95% CI 0.047-0.773, P = 0.020), and IPI score was an independent predictive factor of OS (RR = 0.095, 95% CI 0.011-0.837, P = 0.034). Conclusion The infused CD34+ cell count affects the hematopoietic reconstruction time and component blood transfusion after APBSCT, and has certain predictive value for the prognosis of NHL patients. Key words: Lymphoma, non-Hodgkin; Autologous hematopoietic stem cell transplantation; CD34+ cell count
{"title":"Effects of infused CD34+ cell count on hematopoietic recovery and prognosis of non-Hodgkin lymphoma patients after autologous peripheral blood hematopoietic stem cell transplantation","authors":"Jin Zhao, L. Su, T. Guan, Jiangtao Wang, Xiaolan Liu, Li Ma","doi":"10.3760/CMA.J.CN115356-20190617-00117","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115356-20190617-00117","url":null,"abstract":"Objective \u0000To investigate the effect of infused CD34+ cell count on hematopoietic recovery and prognosis of non-Hodgkin lymphoma (NHL) patients after autologous peripheral blood hematopoietic stem cell transplantation (APBSCT). \u0000 \u0000 \u0000Methods \u0000The data of 60 NHL patients who underwent APBSCT from May 2010 to May 2016 in the Affiliated Cancer Hospital of Shanxi Medical University was retrospectively analyzed, including 32 B-NHL patients and 28 T-NHL patients. The patients were grouped according to the receiver operating characteristic curve (ROC) threshold, and the hematopoietic reconstruction after transplantation was analyzed. The relationship between the infused CD34+ cell count and prognosis was analyzed. The prognostic factors were analyzed using univariate and multivariate analyses. \u0000 \u0000 \u0000Results \u0000The CD34+ cell count threshold was determined to be 4.35×106/kg based on ROC. In CD34+ cell count≥ 4.35×106/kg group (20 cases) and CD34+ cell count 60 years old, Ann Arbor stage Ⅲ-Ⅳ, international prognostic index (IPI) score > 2 and infused CD34+ cell count < 4.35×106/kg (all P < 0.05). Multivariate analysis showed that IPI score and infused CD34+ cell count were both independent predictive factors of PFS (RR = 0.333, 95% CI 0.112-0.994, P = 0.049; RR = 0.190, 95% CI 0.047-0.773, P = 0.020), and IPI score was an independent predictive factor of OS (RR = 0.095, 95% CI 0.011-0.837, P = 0.034). \u0000 \u0000 \u0000Conclusion \u0000The infused CD34+ cell count affects the hematopoietic reconstruction time and component blood transfusion after APBSCT, and has certain predictive value for the prognosis of NHL patients. \u0000 \u0000 \u0000Key words: \u0000Lymphoma, non-Hodgkin; Autologous hematopoietic stem cell transplantation; CD34+ cell count","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"29 1","pages":"165-169"},"PeriodicalIF":0.0,"publicationDate":"2020-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43060316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-03-25DOI: 10.3760/CMA.J.CN115356-20190824-00162
Simeng Chen, Jiakui Zhang, Yingwei Li, Fan Wu, Qianshan Tao, Furun An, Huiping Wang, Ling-xiao Liu, Qing Zhang
Objective To explore the safety and efficacy of chimeric antigen receptor T-cell (CAR-T) therapy for relapsed/refractory acute B-cell lymphoblastic leukemia (B-ALL) with T315I mutation. Methods The clinical data of a patient with relapsed/refractory B-ALL with T315I mutation who underwent CAR-T therapy in the Second Affiliated Hospital of Anhui Medical University was analyzed, and the related literature was reviewed. Results The patient was a 34-year-old man. He was diagnosed with chronic myelogenous leukemia (CML) in January 2017 and started to take imatinib orally. However, the primary affection transformed to B-ALL 4 months later. Because of the E355G gene mutation, the treatment drug was adjusted to dasatinib, and induction chemotherapy was given at the same time. The sequential consolidation chemotherapy was given for 3 times after complete remission (CR). After half a year of remission, T315I mutation was detected and re-induced chemotherapy was given, but ineffective. The patient was treated with CAR-T 3 days after FC regimen (fludarabine 30 mg/m2 per day, day 1 to day 3; cyclophosphamide 200 mg/m2, day 1 to day 3). The number of CD19 CAR-T was 1.0×109, 98% activity degree. Grade 1 cytokine-releasing syndrome appeared after infusion, and was resolved after symptomatic treatment. No serious adverse reactions were observed. CR was achieved half-month after CAR-T treatment, and umbilical cord blood transplantation was successfully performed 1 month later. At the last follow-up, the relapse-free survival time of the patient was 396 days. Conclusion CAR-T therapy may be a new, safe and effective therapy for patients with relapsed/refractory B-ALL with T315I mutation. Key words: Leukemia, B lymphocyte, acute; T315I mutation; Chimeric antigen receptor T-cell
{"title":"Chimeric antigen receptor T-cell therapy for relapsed/refractory acute B-cell lymphoblastic leukemia with T315I mutation: report of one case and review of literature","authors":"Simeng Chen, Jiakui Zhang, Yingwei Li, Fan Wu, Qianshan Tao, Furun An, Huiping Wang, Ling-xiao Liu, Qing Zhang","doi":"10.3760/CMA.J.CN115356-20190824-00162","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115356-20190824-00162","url":null,"abstract":"Objective \u0000To explore the safety and efficacy of chimeric antigen receptor T-cell (CAR-T) therapy for relapsed/refractory acute B-cell lymphoblastic leukemia (B-ALL) with T315I mutation. \u0000 \u0000 \u0000Methods \u0000The clinical data of a patient with relapsed/refractory B-ALL with T315I mutation who underwent CAR-T therapy in the Second Affiliated Hospital of Anhui Medical University was analyzed, and the related literature was reviewed. \u0000 \u0000 \u0000Results \u0000The patient was a 34-year-old man. He was diagnosed with chronic myelogenous leukemia (CML) in January 2017 and started to take imatinib orally. However, the primary affection transformed to B-ALL 4 months later. Because of the E355G gene mutation, the treatment drug was adjusted to dasatinib, and induction chemotherapy was given at the same time. The sequential consolidation chemotherapy was given for 3 times after complete remission (CR). After half a year of remission, T315I mutation was detected and re-induced chemotherapy was given, but ineffective. The patient was treated with CAR-T 3 days after FC regimen (fludarabine 30 mg/m2 per day, day 1 to day 3; cyclophosphamide 200 mg/m2, day 1 to day 3). The number of CD19 CAR-T was 1.0×109, 98% activity degree. Grade 1 cytokine-releasing syndrome appeared after infusion, and was resolved after symptomatic treatment. No serious adverse reactions were observed. CR was achieved half-month after CAR-T treatment, and umbilical cord blood transplantation was successfully performed 1 month later. At the last follow-up, the relapse-free survival time of the patient was 396 days. \u0000 \u0000 \u0000Conclusion \u0000CAR-T therapy may be a new, safe and effective therapy for patients with relapsed/refractory B-ALL with T315I mutation. \u0000 \u0000 \u0000Key words: \u0000Leukemia, B lymphocyte, acute; T315I mutation; Chimeric antigen receptor T-cell","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"29 1","pages":"170-174"},"PeriodicalIF":0.0,"publicationDate":"2020-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46676662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: To improve the understanding of extranodal nasal type NK/T cell lymphoma with lipoid pneumonia and prevent misdiagnosis and missed diagnosis. Method: A retrospective analysis was conducted on the diagnosis and treatment of a patient with extranodal nasal type NK/T cell lymphoma complicated with lipoid pneumonia admitted to Jiangsu Cancer Hospital, and relevant literature was reviewed. As a result, the patient developed new lung lesions during the anti-tumor process, and considering inflammation, the possibility of tumor infiltration was not ruled out. However, the anti infection treatment was ineffective, and the lesion gradually progressed, suspected to be tumor infiltration. After repeatedly inquiring about the medical history and conducting lung biopsy, the diagnosis was confirmed as lipoid pneumonia. After treatment with hormones, it gradually improved. Conclusion: Extranodal nasal type NK/T cell lymphoma combined with lipoid pneumonia is relatively rare in clinical practice, and the clinical manifestations are non-specific. Lung biopsy is helpful for diagnosis.
{"title":"Extranodal nasal-type NK/T cell lymphoma with lipoid pneumonia: report of one case and review of literature","authors":"Jiali Zhu, Yan Zhang","doi":"10.3760/CMA.J.CN115356-20190725-00142","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115356-20190725-00142","url":null,"abstract":"目的 \u0000提高对结外鼻型NK/T细胞淋巴瘤合并类脂性肺炎的认识，防止误诊、漏诊。 \u0000 \u0000 \u0000方法 \u0000回顾性分析江苏省肿瘤医院收治的1例结外鼻型NK/T细胞淋巴瘤合并类脂性肺炎患者的诊疗经过，并复习相关文献。 \u0000 \u0000 \u0000结果 \u0000该患者抗肿瘤过程中出现新的肺部病灶，考虑炎症，不排除肿瘤浸润的可能，但抗感染治疗无效，病灶逐渐进展，疑诊为肿瘤浸润。后经反复询问病史并行肺活组织检查，确诊为类脂性肺炎，经激素等治疗后逐渐好转。 \u0000 \u0000 \u0000结论 \u0000结外鼻型NK/T细胞淋巴瘤合并类脂性肺炎临床上较为罕见，临床表现无特异性，肺活组织检查有助于诊断。","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"29 1","pages":"183-185"},"PeriodicalIF":0.0,"publicationDate":"2020-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45881902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-03-25DOI: 10.3760/CMA.J.CN115356-20191012-00199
Bin Yang, Wei-Tzu Cheng
Objective To investigate the clinical features, diagnosis, treatment and prognosis of primary testicular diffuse large B-cell lymphoma (PT-DLBCL). Methods The clinical data of 2 patients with PT-DLBCL in the Second People's Hospital of Lianyungang treated in May 2013 and April 2018 was retrospectively analyzed. The clinical features, diagnosis, treatment and prognosis of PT-DLBCL were summarized with review of these 2 cases combining with other 42 cases reported in domestic literature. Results Case 1, a 71 years old man, complained of bilateral scrotal enlargement with pain and discomfort for 2 months. Case 2, an 85 years old man, presented with left scrotal mass for 3 months. All 2 patients underwent orchiectomy. Both of the 2 patients were diagnosed as PT-DLBCL and non-germinal center B-cell (non-GCB) subtype and had Ann Arbor stage ⅠE after operation. Case 1 received only 2 cycles of CHOP (cyclophosphamide, epirubicin, vincristine, prednisone) due to lack of financial support. Case 2 refused chemotherapy and right testis irradiation because of advanced age. They were followed up for 71 months and 12 months, respectively. They were both alive without recurrence at last time of the follow-up. The median age of 44 patients (2 cases in this study and 42 cases reported in the domestic literature) was 64 years old (range 45-87 years old). The most common symptom was unilateral painless testicular swelling (left testis 17 cases and right testis 24 cases). Twenty-one patients were Ann Arbor stage Ⅰ, 6 patients were stage Ⅱ, 6 patients were stage Ⅲ, and 11 patients were stage Ⅳ. Thirty-one patients were non-GCB subtype. Twelve patients were international prognostic index (IPI) score ≥3. Serum lactate dehydrogenase (LDH) level was elevated in 13 patients. All patients underwent orchiectomy. CHOP/R-CHOP chemotherapy was given to 40 patients and prophylactic radiation to contralateral testis was given to 12 patients. Twenty-two patients received prophylactic intrathecal chemotherapy. After a median follow-up of 17 months (range 3-135 months), 14 patients died and the median overall survival time was 13 months (range 3-96 months). Conclusions PT-DLBCL is rare. Its diagnosis mainly depends on pathology, with the majority of patients diagnosed in early Ann Arbor clinical stage and non-GCB subtype. The radical orchiectomy and R-CHOP chemotherapy is recommended due to local relapse and systemic dissemination. It is curable in the early stage while patients with advanced stage have a very poor prognosis. Prophylactic radiation to contralateral testis and intrathecal chemotherapy can decrease the risk of recurrence. Key words: Testicular neoplasms; Lymphoma, large B-cell, diffuse; Diagnosis; Treatment; Prognosis
{"title":"Clinical analysis of primary testicular diffuse large B-cell lymphoma","authors":"Bin Yang, Wei-Tzu Cheng","doi":"10.3760/CMA.J.CN115356-20191012-00199","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115356-20191012-00199","url":null,"abstract":"Objective \u0000To investigate the clinical features, diagnosis, treatment and prognosis of primary testicular diffuse large B-cell lymphoma (PT-DLBCL). \u0000 \u0000 \u0000Methods \u0000The clinical data of 2 patients with PT-DLBCL in the Second People's Hospital of Lianyungang treated in May 2013 and April 2018 was retrospectively analyzed. The clinical features, diagnosis, treatment and prognosis of PT-DLBCL were summarized with review of these 2 cases combining with other 42 cases reported in domestic literature. \u0000 \u0000 \u0000Results \u0000Case 1, a 71 years old man, complained of bilateral scrotal enlargement with pain and discomfort for 2 months. Case 2, an 85 years old man, presented with left scrotal mass for 3 months. All 2 patients underwent orchiectomy. Both of the 2 patients were diagnosed as PT-DLBCL and non-germinal center B-cell (non-GCB) subtype and had Ann Arbor stage ⅠE after operation. Case 1 received only 2 cycles of CHOP (cyclophosphamide, epirubicin, vincristine, prednisone) due to lack of financial support. Case 2 refused chemotherapy and right testis irradiation because of advanced age. They were followed up for 71 months and 12 months, respectively. They were both alive without recurrence at last time of the follow-up. The median age of 44 patients (2 cases in this study and 42 cases reported in the domestic literature) was 64 years old (range 45-87 years old). The most common symptom was unilateral painless testicular swelling (left testis 17 cases and right testis 24 cases). Twenty-one patients were Ann Arbor stage Ⅰ, 6 patients were stage Ⅱ, 6 patients were stage Ⅲ, and 11 patients were stage Ⅳ. Thirty-one patients were non-GCB subtype. Twelve patients were international prognostic index (IPI) score ≥3. Serum lactate dehydrogenase (LDH) level was elevated in 13 patients. All patients underwent orchiectomy. CHOP/R-CHOP chemotherapy was given to 40 patients and prophylactic radiation to contralateral testis was given to 12 patients. Twenty-two patients received prophylactic intrathecal chemotherapy. After a median follow-up of 17 months (range 3-135 months), 14 patients died and the median overall survival time was 13 months (range 3-96 months). \u0000 \u0000 \u0000Conclusions \u0000PT-DLBCL is rare. Its diagnosis mainly depends on pathology, with the majority of patients diagnosed in early Ann Arbor clinical stage and non-GCB subtype. The radical orchiectomy and R-CHOP chemotherapy is recommended due to local relapse and systemic dissemination. It is curable in the early stage while patients with advanced stage have a very poor prognosis. Prophylactic radiation to contralateral testis and intrathecal chemotherapy can decrease the risk of recurrence. \u0000 \u0000 \u0000Key words: \u0000Testicular neoplasms; Lymphoma, large B-cell, diffuse; Diagnosis; Treatment; Prognosis","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"29 1","pages":"179-182"},"PeriodicalIF":0.0,"publicationDate":"2020-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45932114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：